The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...
Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019, but could only be prescribed ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Phenylephrine is a commonly used ingredient in cold and flu medications as a nasal and sinus decongestant. It is present in several on-the-shelf cold and flu medications in New Zealand, including ...
Pharmaceutical Technology on MSN10d
Supernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
The global U.S. Nasal Spray Market is expected to grow at 6.9% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...
Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback